title: A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation.
abstract: BACKGROUND
  Anemia after kidney transplantation has been associated with poor transplant outcomes. We hypothesized that intravenous (IV) iron may more rapidly correct anemia than oral (PO) iron.
  
  
  METHODS
  One hundred four kidney transplant recipients were prospectively randomized to IV iron polymaltose (500 mg single dose) or PO ferrous sulfate (210 mg elemental iron daily, continuously). The primary outcome was time to resolution of anemia, defined as hemoglobin more than or equal to 11 g/dL. Secondary outcomes included infections, blood transfusions, gastrointestinal side-effects, and acute rejection.
  
  
  RESULTS
  There was no significant difference in the primary outcome comparing IV with PO iron (hazards ratio 1.22; 95% confidence interval 0.82-1.83; P=0.32). The median time to resolution of anemia was 12 days in the IV group versus 21 days in the PO group. There were no differences in infections (20% vs. 24%, P=0.62), acute rejection (8% vs. 6%, P=0.68), blood transfusions (10% vs. 18%, P=0.24), and severe gastrointestinal side-effects (6% vs. 12%, P=0.29) between the IV iron and the PO iron groups.
  
  
  CONCLUSIONS
  We conclude that a single dose of IV iron did not result in more rapid resolution of anemia compared with PO iron. Both IV and PO iron are safe and effective in the management of posttransplant anemia.
authors.affiliation: Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia. david_mudge@health.qld.gov.au
authors.forename: David W
authors.initials: DW
authors.lastname: Mudge
authors.forename: Ken-Soon
authors.initials: KS
authors.lastname: Tan
authors.forename: Rhianna
authors.initials: R
authors.lastname: Miles
authors.forename: David W
authors.initials: DW
authors.lastname: Johnson
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Badve
authors.forename: Scott B
authors.initials: SB
authors.lastname: Campbell
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Isbel
authors.forename: Carolyn L
authors.initials: CL
authors.lastname: van Eps
authors.forename: Carmel M
authors.initials: CM
authors.lastname: Hawley
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D001803:Blood Transfusion; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D005296:Ferrous Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D006084:Graft Rejection; D006801:Humans; D007239:Infections / Q000209:etiology; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D005296:Ferrous Compounds; D011134:Polysaccharides; C539743:iron polyisomaltosate; C020748:ferrous sulfate